Anti-VEGF Injection Regimen For AMD Still Unclear, Speaker Says | OphthalmologyWeb: The Ultimate Online Resource for Ophthalmologists

Tuesday, September 7, 2010

Email

Comments

Ocular Surgery News

Although the largest trials on anti-VEGF therapy in age-related macular degeneration have shown that best possible outcomes are obtained with monthly injections, doubts remain on whether this fixed-dosing regimen is suitable for all patients, according to one speaker here.

Retina Products and Equipment »

All of the following drugs are FDA approved for the treatment of predominantly classic subfoveal CNV in patients with neovascular AMD except for which one?
1. Pegaptanib sodium (Macugen)
2. Verteporfin (Visudyne PDT)
3. Ranibizumab (Lucentis)
4. Bevacizumab (Avastin)
5. All of the above
Check The Answer

CareCloud Charts For Ophthalmology
Get all of the tools you need to deliver... view product
Selecta Trio™ YAG Laser, SLT and Photocoagulation
The Lumenis Selecta® Trio™ ... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us